Dimitrios V. Vavoulis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dimitrios V. Vavoulis has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Anna Schuh
Department of Oncology, University of Oxford, Oxford, UK
12 shared publications Anthony Cutts
University of Oxford, Oxford, UK
7 shared publicationsHelene Dreau
University of Oxford, Oxford, UK
6 shared publicationsLulu Chirande
Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania
5 shared publications- Liz Morrell
Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
4 shared publications Paul Ntemi
Bugando Medical Centre
4 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1754-1762
Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas
Burkitt’s lymphoma (BL) is common in sub-Saharan Africa, yet diagnosis is often delayed due to limited pathology capacity. Here we evaluated blood-based liquid biopsies from 377 children and young adults with clinically suspected lymphoma at four hospitals in Tanzania and Uganda, assessing diagnostic accuracy and turnaround time (TAT). After extensive pathology capacity building, a gold-standard diagnosis was established using tissue morphology, a limited validated immunohistochemistry panel and independent dual histopathologist review. Using clinical features and circulating tumor DNA markers ( MYC mutations, MYC –immunoglobulin translocations and Epstein–Barr virus fragmentomics), we trained six penalized logistic regression models with tenfold crossvalidation ( n = 212). The best-performing model was externally validated in a prospective real-world cohort ( n = 56). Diagnostic accuracy, yield and TAT were compared head to head between liquid biopsy and the gold standard in 58 participants. The comprehensive model achieved the highest performance (area under the curve (AUC) 0.95, 95% confidence interval (95% CI) 0.901–0.981, sensitivity 0.86, specificity 0.95), confirmed by external validation (AUC 0.98, 95% CI 0.942–1.000). Liquid biopsy was the only diagnostic result available at the multidisciplinary review in 42% of participants and reduced median diagnostic TAT from 46.8 d to 6.5 d ( P = 4.42 × 10 −10 ). These findings demonstrate that liquid biopsy enables fast, highly accurate molecular diagnosis of EBV + BL and may substantially reduce treatment delays in resource-limited settings.
- 19 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1754-1762
Open AccessLiquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas
Burkitt’s lymphoma (BL) is common in sub-Saharan Africa, yet diagnosis is often delayed due to limited pathology capacity. Here we evaluated blood-based liquid biopsies from 377 children and young adults with clinically suspected lymphoma at four hospitals in Tanzania and Uganda, assessing diagnostic accuracy and turnaround time (TAT). After extensive pathology capacity building, a gold-standard diagnosis was established using tissue morphology, a limited validated immunohistochemistry panel and independent dual histopathologist review. Using clinical features and circulating tumor DNA markers ( MYC mutations, MYC –immunoglobulin translocations and Epstein–Barr virus fragmentomics), we trained six penalized logistic regression models with tenfold crossvalidation ( n = 212). The best-performing model was externally validated in a prospective real-world cohort ( n = 56). Diagnostic accuracy, yield and TAT were compared head to head between liquid biopsy and the gold standard in 58 participants. The comprehensive model achieved the highest performance (area under the curve (AUC) 0.95, 95% confidence interval (95% CI) 0.901–0.981, sensitivity 0.86, specificity 0.95), confirmed by external validation (AUC 0.98, 95% CI 0.942–1.000). Liquid biopsy was the only diagnostic result available at the multidisciplinary review in 42% of participants and reduced median diagnostic TAT from 46.8 d to 6.5 d ( P = 4.42 × 10 −10 ). These findings demonstrate that liquid biopsy enables fast, highly accurate molecular diagnosis of EBV + BL and may substantially reduce treatment delays in resource-limited settings.
- Open Access
- 17 October 2025
- Published by Springer Nature in Research Square
Evidence of latent-lytic replication in EBV-positive Burkitt lymphoma from whole genome and transcriptome sequencing
Epstein–Barr virus (EBV) is a ubiquitous human herpesvirus linked to multiple malignancies, but its role in disease remains uncertain. We analysed 410 EBV genomes, including 64 newly sequenced isolates from plasma of East African children with and without Burkitt lymphoma (BL), integrating whole-genome and transcriptomic data. Population genomic analyses revealed marked regional structure with strain-level diversity shaped by both recombination and mutation, particularly within latency and immune-evasion genes (EBNA-1, LMP-1, BCRF1, BNLF2a), reflecting selective pressure from host immunity and tumour microenvironment. We identified a BL-associated mutational signature (SBS_EBV3) enriched for T > C and C > T substitutions in G-rich contexts, with limited similarity to known COSMIC signatures (closest match SBS54, cosine similarity 0.74). Transcriptomic profiling demonstrated a mixed latent–lytic expression programme in BL, potentially promoting recombination and mutagenesis. These findings define new features of EBV evolution in BL and highlight opportunities for diagnostics and vaccines targeting both latent and lytic antigens.
- 17 October 2025
- Published by Springer Nature in Research Square
Open AccessEvidence of latent-lytic replication in EBV-positive Burkitt lymphoma from whole genome and transcriptome sequencing
Epstein–Barr virus (EBV) is a ubiquitous human herpesvirus linked to multiple malignancies, but its role in disease remains uncertain. We analysed 410 EBV genomes, including 64 newly sequenced isolates from plasma of East African children with and without Burkitt lymphoma (BL), integrating whole-genome and transcriptomic data. Population genomic analyses revealed marked regional structure with strain-level diversity shaped by both recombination and mutation, particularly within latency and immune-evasion genes (EBNA-1, LMP-1, BCRF1, BNLF2a), reflecting selective pressure from host immunity and tumour microenvironment. We identified a BL-associated mutational signature (SBS_EBV3) enriched for T > C and C > T substitutions in G-rich contexts, with limited similarity to known COSMIC signatures (closest match SBS54, cosine similarity 0.74). Transcriptomic profiling demonstrated a mixed latent–lytic expression programme in BL, potentially promoting recombination and mutagenesis. These findings define new features of EBV evolution in BL and highlight opportunities for diagnostics and vaccines targeting both latent and lytic antigens.
- Open Access
- 14 July 2025
- Published by Springer Nature in Research Square
Clinical Validation of Liquid Biopsy for Faster Molecular Diagnosis of EBV-Positive Burkitt Lymphoma
Burkitt Lymphoma (BL) is common in sub-Saharan Africa, but its diagnosis is often delayed. Here, we comprehensively evaluate blood-based liquid biopsies from 377 children and young adults with clinically suspected lymphoma for diagnostic accuracy, yield and turnaround time (TAT). Following extensive pathology capacity building at participating study pathology sites to streamline and quality-ensure the histopathology assessment, diagnoses were reached from best local pathology consisting of tissue morphology, a previously validated limited immunohistochemistry (IHC) panel and review by at least two histopathologists, together called the “gold standard”. Next, we used a combination of clinical characteristics and circulating tumour DNA attributes ( MYC mutations, MYC-IG translocations, and EBV fragmentomics) to train five different diagnostic models based on penalised logistic regression and 10-fold cross-validation on 212 children and young adults with clinically suspected lymphoma. External real-world validation was conducted on the best-performing model on a prospective cohort of 56 children and young adults with clinically suspected lymphoma. Diagnostic accuracy, yield and TAT for the liquid biopsy test were compared head-to-head against the gold-standard in 58 children and young adults with clinically suspected lymphoma. All five models showed good discrimination for BL (AUC ≥ 0.8). The comprehensive model had the best overall performance with AUC of 0.94 (95% CI: 0.895–0.974; p = 4.86×10⁻⁴), sensitivity of 0.83, and specificity of 0.95 confirmed by external validation (AUC of 0.98 (95% CI: 0.942–1)). Liquid biopsy was the only diagnostic result available in the multi-disciplinary team meeting in 42% (26/61) of participants and reduced the median diagnostic TAT from 46.8 days to 6.5 days (p = 4.42e-10) compared to gold standard. This study demonstrates that our liquid biopsy model enables fast, highly accurate molecular diagnosis of EBV-positive BL. Its future integration into the diagnostic pathway may increase diagnostic accuracy and minimise treatment delays in resource-limited settings.
- 14 July 2025
- Published by Springer Nature in Research Square
Open AccessClinical Validation of Liquid Biopsy for Faster Molecular Diagnosis of EBV-Positive Burkitt Lymphoma
Burkitt Lymphoma (BL) is common in sub-Saharan Africa, but its diagnosis is often delayed. Here, we comprehensively evaluate blood-based liquid biopsies from 377 children and young adults with clinically suspected lymphoma for diagnostic accuracy, yield and turnaround time (TAT). Following extensive pathology capacity building at participating study pathology sites to streamline and quality-ensure the histopathology assessment, diagnoses were reached from best local pathology consisting of tissue morphology, a previously validated limited immunohistochemistry (IHC) panel and review by at least two histopathologists, together called the “gold standard”. Next, we used a combination of clinical characteristics and circulating tumour DNA attributes ( MYC mutations, MYC-IG translocations, and EBV fragmentomics) to train five different diagnostic models based on penalised logistic regression and 10-fold cross-validation on 212 children and young adults with clinically suspected lymphoma. External real-world validation was conducted on the best-performing model on a prospective cohort of 56 children and young adults with clinically suspected lymphoma. Diagnostic accuracy, yield and TAT for the liquid biopsy test were compared head-to-head against the gold-standard in 58 children and young adults with clinically suspected lymphoma. All five models showed good discrimination for BL (AUC ≥ 0.8). The comprehensive model had the best overall performance with AUC of 0.94 (95% CI: 0.895–0.974; p = 4.86×10⁻⁴), sensitivity of 0.83, and specificity of 0.95 confirmed by external validation (AUC of 0.98 (95% CI: 0.942–1)). Liquid biopsy was the only diagnostic result available in the multi-disciplinary team meeting in 42% (26/61) of participants and reduced the median diagnostic TAT from 46.8 days to 6.5 days (p = 4.42e-10) compared to gold standard. This study demonstrates that our liquid biopsy model enables fast, highly accurate molecular diagnosis of EBV-positive BL. Its future integration into the diagnostic pathway may increase diagnostic accuracy and minimise treatment delays in resource-limited settings.
- Open Access
- 14 May 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (10) , 2393-2401
Rituximab for children with EBV-positive Burkitt lymphoma in East Africa
The addition of rituximab to the chemotherapy backbone was shown to significantly improve outcomes of children with aggressive high-grade lymphomas in high-income countries. However, data on its safety and efficacy in children with Epstein-Barr virus (EBV)–positive Burkitt lymphoma (BL) are limited. We conducted a prospective nonrandomized observational study in East African patients aged ≤25 years with confirmed BL. Patients received either the International Network for Cancer Treatment and Research (INCTR)–based standard chemotherapy (cyclophosphamide, vincristine, and methotrexate [COM]) or rituximab plus standard chemotherapy (R-COM). The primary end point was safety. The secondary outcomes were event-free and overall survival and cost-effectiveness of incorporating rituximab. Primary analyses were conducted in the intention-to-treat population. The median follow-up was 23 months. Safety analyses included 72 patients: 32 in the COM group and 40 in the R-COM group. Grade ≥3 adverse events occurred in 18% of R-COM patients and 16% of COM patients. With respect to treatment outcomes at 12 months, 5 events were observed in the R-COM group and 14 in the COM group. The 12-month event-free survival was 67% with R-COM and 43% with COM (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24-0.98; P = .045). There were 8 deaths in the R-COM group, whereas 16 patients died in the COM group (HR, 0.32; 95% CI, 0.14-0.75; P = .009). R-COM was particularly effective in advanced-stage disease. The addition of rituximab to the INCTR-based protocol (COM) for EBV-positive BL has been observed to be safe and feasible in experienced centers in East Africa and saves lives.
- 14 May 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (10) , 2393-2401
Open AccessRituximab for children with EBV-positive Burkitt lymphoma in East Africa
The addition of rituximab to the chemotherapy backbone was shown to significantly improve outcomes of children with aggressive high-grade lymphomas in high-income countries. However, data on its safety and efficacy in children with Epstein-Barr virus (EBV)–positive Burkitt lymphoma (BL) are limited. We conducted a prospective nonrandomized observational study in East African patients aged ≤25 years with confirmed BL. Patients received either the International Network for Cancer Treatment and Research (INCTR)–based standard chemotherapy (cyclophosphamide, vincristine, and methotrexate [COM]) or rituximab plus standard chemotherapy (R-COM). The primary end point was safety. The secondary outcomes were event-free and overall survival and cost-effectiveness of incorporating rituximab. Primary analyses were conducted in the intention-to-treat population. The median follow-up was 23 months. Safety analyses included 72 patients: 32 in the COM group and 40 in the R-COM group. Grade ≥3 adverse events occurred in 18% of R-COM patients and 16% of COM patients. With respect to treatment outcomes at 12 months, 5 events were observed in the R-COM group and 14 in the COM group. The 12-month event-free survival was 67% with R-COM and 43% with COM (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24-0.98; P = .045). There were 8 deaths in the R-COM group, whereas 16 patients died in the COM group (HR, 0.32; 95% CI, 0.14-0.75; P = .009). R-COM was particularly effective in advanced-stage disease. The addition of rituximab to the INCTR-based protocol (COM) for EBV-positive BL has been observed to be safe and feasible in experienced centers in East Africa and saves lives.
- Open Access
- 8 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals
The analysis of circulating tumour DNA (ctDNA) through minimally invasive liquid biopsies is promising for early multi-cancer detection and monitoring minimal residual disease. Most existing methods focus on targeted deep sequencing, but few integrate multiple data modalities. Here, we develop a methodology for ctDNA detection using deep (80x) whole-genome TET-Assisted Pyridine Borane Sequencing (TAPS), a less destructive approach than bisulphite sequencing, which permits the simultaneous analysis of genomic and methylomic data. We conduct a diagnostic accuracy study across multiple cancer types in symptomatic patients, achieving 94.9% sensitivity and 88.8% specificity. Matched tumour biopsies are used for validation, not for guiding the analysis, imitating an early detection scenario. Furthermore, in silico validation demonstrates strong discrimination (86% AUC) at ctDNA fractions as low as 0.7%. Additionally, we successfully track tumour burden and ctDNA shedding from precancerous lesions post-treatment without requiring matched tumour biopsies. This pipeline is ready for further clinical evaluation to extend cancer screening and improve patient triage and monitoring.
- 8 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessMultimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals
The analysis of circulating tumour DNA (ctDNA) through minimally invasive liquid biopsies is promising for early multi-cancer detection and monitoring minimal residual disease. Most existing methods focus on targeted deep sequencing, but few integrate multiple data modalities. Here, we develop a methodology for ctDNA detection using deep (80x) whole-genome TET-Assisted Pyridine Borane Sequencing (TAPS), a less destructive approach than bisulphite sequencing, which permits the simultaneous analysis of genomic and methylomic data. We conduct a diagnostic accuracy study across multiple cancer types in symptomatic patients, achieving 94.9% sensitivity and 88.8% specificity. Matched tumour biopsies are used for validation, not for guiding the analysis, imitating an early detection scenario. Furthermore, in silico validation demonstrates strong discrimination (86% AUC) at ctDNA fractions as low as 0.7%. Additionally, we successfully track tumour burden and ctDNA shedding from precancerous lesions post-treatment without requiring matched tumour biopsies. This pipeline is ready for further clinical evaluation to extend cancer screening and improve patient triage and monitoring.
- Open Access
Multimodal cell-free DNA whole-genome analysis combined with TET-Assisted Pyridine Borane Sequencing is sensitive and reveals specific cancer signals
The analysis of circulating tumour DNA (ctDNA) promises to extend current tissue-specific cancer screening programmes to multi-cancer early detection and measurable disease monitoring to solid tumours using minimally invasive blood draws (liquid biopsies). Most studies so far have focussed on using targeted deep sequencing to detect the low-abundance, fragmented ctDNA. A few studies have integrated information from multiple modalities using shallow 1× WGS. Here, we developed an integrated bioinformatics pipeline for ctDNA detection based on whole genome TET-Assisted Pyridine Borane Sequencing (TAPS) of plasma samples sequenced at 80× or higher. We conducted a diagnostic accuracy study in a case-control cohort of patients presenting to the UK National Health Service’s (NHS) primary care pathway with non-specific symptoms of cancer, who either did not have cancer or who were subsequently diagnosed with cancer and referred to surgery with curative intent. TAPS is a base-level-resolution sequencing methodology for the detection of 5-methylcytosines and 5-hydro-methylcytosines. Unlike bisulfite-sequencing, the current established method for mapping epigenetic DNA modifications, TAPS is a non-destructive methodology, which only converts methylated cytosines and preserves DNA fragments over 10 kilobases long, thus opening the possibility of simultaneous methylome and genome analysis on the same sequencing data. The proposed methodology combines copy number aberrations and single nucleotide variants with methylation calls from TAPS-treated plasma from patients with Stage 1-4 colorectal (n=36), oesophageal (n=8), pancreatic (n=6), renal (n=5), ovarian (n=4) and breast (n=2) cancers. Plasma samples from 21 confirmed non-cancer controls were used for data denoising, while plasma samples from 9 additional agematched healthy controls were further used to establish the minimum level of detection. Copy number aberrations, single nucleotide variants, and methylation signals were independently analysed and combined in sample-specific scores, which quantify the levels of plasma ctDNA. Matched tumour samples were used for validation, not for guiding the analysis, imitating an early detection scenario. The detection threshold was set such that specificity was 100%, resulting in sensitivity of 85.2%. In silico experiments on high-fidelity synthetic data suggest excellent discriminatory capacity (AUC > 80%) at ctDNA fractions as low as 0.7%. Furthermore, we demonstrate successful tracking of tumour burden post-treatment and ctDNA shedding in precancerous adenomas in patients with colorectal cancer in the absence of a matched tumour biopsy. In summary, we developed and validated a pipeline for interrogating liquid biopsies using TAPS 80× or higher WGS that is ready for in-depth clinical evaluation both in multi-cancer screening of high-risk individuals and multi-cancer measurable disease monitoring.
Open AccessMultimodal cell-free DNA whole-genome analysis combined with TET-Assisted Pyridine Borane Sequencing is sensitive and reveals specific cancer signals
The analysis of circulating tumour DNA (ctDNA) promises to extend current tissue-specific cancer screening programmes to multi-cancer early detection and measurable disease monitoring to solid tumours using minimally invasive blood draws (liquid biopsies). Most studies so far have focussed on using targeted deep sequencing to detect the low-abundance, fragmented ctDNA. A few studies have integrated information from multiple modalities using shallow 1× WGS. Here, we developed an integrated bioinformatics pipeline for ctDNA detection based on whole genome TET-Assisted Pyridine Borane Sequencing (TAPS) of plasma samples sequenced at 80× or higher. We conducted a diagnostic accuracy study in a case-control cohort of patients presenting to the UK National Health Service’s (NHS) primary care pathway with non-specific symptoms of cancer, who either did not have cancer or who were subsequently diagnosed with cancer and referred to surgery with curative intent. TAPS is a base-level-resolution sequencing methodology for the detection of 5-methylcytosines and 5-hydro-methylcytosines. Unlike bisulfite-sequencing, the current established method for mapping epigenetic DNA modifications, TAPS is a non-destructive methodology, which only converts methylated cytosines and preserves DNA fragments over 10 kilobases long, thus opening the possibility of simultaneous methylome and genome analysis on the same sequencing data. The proposed methodology combines copy number aberrations and single nucleotide variants with methylation calls from TAPS-treated plasma from patients with Stage 1-4 colorectal (n=36), oesophageal (n=8), pancreatic (n=6), renal (n=5), ovarian (n=4) and breast (n=2) cancers. Plasma samples from 21 confirmed non-cancer controls were used for data denoising, while plasma samples from 9 additional agematched healthy controls were further used to establish the minimum level of detection. Copy number aberrations, single nucleotide variants, and methylation signals were independently analysed and combined in sample-specific scores, which quantify the levels of plasma ctDNA. Matched tumour samples were used for validation, not for guiding the analysis, imitating an early detection scenario. The detection threshold was set such that specificity was 100%, resulting in sensitivity of 85.2%. In silico experiments on high-fidelity synthetic data suggest excellent discriminatory capacity (AUC > 80%) at ctDNA fractions as low as 0.7%. Furthermore, we demonstrate successful tracking of tumour burden post-treatment and ctDNA shedding in precancerous adenomas in patients with colorectal cancer in the absence of a matched tumour biopsy. In summary, we developed and validated a pipeline for interrogating liquid biopsies using TAPS 80× or higher WGS that is ready for in-depth clinical evaluation both in multi-cancer screening of high-risk individuals and multi-cancer measurable disease monitoring.
- Open Access
- 25 August 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (17) , 4962-4965
Treatment delays in children and young adults with lymphoma: a report from an East Africa lymphoma cohort study
- 25 August 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (17) , 4962-4965
Open AccessTreatment delays in children and young adults with lymphoma: a report from an East Africa lymphoma cohort study
- Open Access
- 4 November 2022
- Published by Springer Nature in Nature Genetics
- Vol. 54 (11) , 1675-1689
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer patients is debated. Here, we report the whole-genome sequencing of 485 chronic lymphocytic leukemia patients enrolled in clinical trials as part of the United Kingdom’s 100,000 Genomes Project. We identify an extended catalog of recurrent coding and noncoding genetic mutations that represents a source for future studies and provide the most complete high-resolution map of structural variants, copy number changes and global genome features including telomere length, mutational signatures and genomic complexity. We demonstrate the relationship of these features with clinical outcome and show that integration of 186 distinct recurrent genomic alterations defines five genomic subgroups that associate with response to therapy, refining conventional outcome prediction. While requiring independent validation, our findings highlight the potential of whole-genome sequencing to inform future risk stratification in chronic lymphocytic leukemia.
- 4 November 2022
- Published by Springer Nature in Nature Genetics
- Vol. 54 (11) , 1675-1689
Open AccessWhole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer patients is debated. Here, we report the whole-genome sequencing of 485 chronic lymphocytic leukemia patients enrolled in clinical trials as part of the United Kingdom’s 100,000 Genomes Project. We identify an extended catalog of recurrent coding and noncoding genetic mutations that represents a source for future studies and provide the most complete high-resolution map of structural variants, copy number changes and global genome features including telomere length, mutational signatures and genomic complexity. We demonstrate the relationship of these features with clinical outcome and show that integration of 186 distinct recurrent genomic alterations defines five genomic subgroups that associate with response to therapy, refining conventional outcome prediction. While requiring independent validation, our findings highlight the potential of whole-genome sequencing to inform future risk stratification in chronic lymphocytic leukemia.
- Open Access
- 20 May 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (20) , 2800-2816
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia
The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosis. In this study, we conducted whole-genome sequencing (WGS) of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS) from 17 patients recruited into a clinical trial (CHOP-O). We found that tissue-RS was enriched for mutations in poor-risk CLL drivers and genes in the DNA damage response (DDR) pathway. In addition, we identified genomic aberrations not previously implicated in RS, including the protein tyrosine phosphatase receptor (PTPRD) and tumor necrosis factor receptor–associated factor 3 (TRAF3). In the noncoding genome, we discovered activation-induced cytidine deaminase–related and unrelated kataegis in tissue-RS affecting regulatory regions of key immune-regulatory genes. These include BTG2, CXCR4, NFATC1, PAX5, NOTCH-1, SLC44A5, FCRL3, SELL, TNIP2, and TRIM13. Furthermore, differences between the global mutation signatures of pairs of PB-CLL and tissue-RS samples implicate DDR as the dominant mechanism driving transformation. Pathway-based clonal deconvolution analysis showed that genes in the MAPK and DDR pathways demonstrate high clonal-expansion probability. Direct comparison of nodal-CLL and tissue-RS pairs from an independent cohort confirmed differential expression of the same pathways by RNA expression profiling. Our integrated analysis of WGS and RNA expression data significantly extends previous targeted approaches, which were limited by the lack of germline samples, and it facilitates the identification of novel genomic correlates implicated in RS transformation, which could be targeted therapeutically. Our results inform the future selection of investigative agents for a UK clinical platform study. This trial was registered at www.clinicaltrials.gov as #NCT03899337.
- 20 May 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (20) , 2800-2816
Open AccessGenomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia
The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosis. In this study, we conducted whole-genome sequencing (WGS) of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS) from 17 patients recruited into a clinical trial (CHOP-O). We found that tissue-RS was enriched for mutations in poor-risk CLL drivers and genes in the DNA damage response (DDR) pathway. In addition, we identified genomic aberrations not previously implicated in RS, including the protein tyrosine phosphatase receptor (PTPRD) and tumor necrosis factor receptor–associated factor 3 (TRAF3). In the noncoding genome, we discovered activation-induced cytidine deaminase–related and unrelated kataegis in tissue-RS affecting regulatory regions of key immune-regulatory genes. These include BTG2, CXCR4, NFATC1, PAX5, NOTCH-1, SLC44A5, FCRL3, SELL, TNIP2, and TRIM13. Furthermore, differences between the global mutation signatures of pairs of PB-CLL and tissue-RS samples implicate DDR as the dominant mechanism driving transformation. Pathway-based clonal deconvolution analysis showed that genes in the MAPK and DDR pathways demonstrate high clonal-expansion probability. Direct comparison of nodal-CLL and tissue-RS pairs from an independent cohort confirmed differential expression of the same pathways by RNA expression profiling. Our integrated analysis of WGS and RNA expression data significantly extends previous targeted approaches, which were limited by the lack of germline samples, and it facilitates the identification of novel genomic correlates implicated in RS transformation, which could be targeted therapeutically. Our results inform the future selection of investigative agents for a UK clinical platform study. This trial was registered at www.clinicaltrials.gov as #NCT03899337.
- Open Access
- 28 July 2020
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 37 (2) , 147-154
A statistical approach for tracking clonal dynamics in cancer using longitudinal next-generation sequencing data
Tumours are composed of distinct cancer cell populations (clones), which continuously adapt to their local micro-environment. Standard methods for clonal deconvolution seek to identify groups of mutations and estimate the prevalence of each group in the tumour, while considering its purity and copy number profile. These methods have been applied on cross-sectional data and on longitudinal data after discarding information on the timing of sample collection. Two key questions are how can we incorporate such information in our analyses and is there any benefit in doing so? We developed a clonal deconvolution method, which incorporates explicitly the temporal spacing of longitudinally sampled tumours. By merging a Dirichlet Process Mixture Model with Gaussian Process priors and using as input a sequence of several sparsely collected samples, our method can reconstruct the temporal profile of the abundance of any mutation cluster supported by the data as a continuous function of time. We benchmarked our method on whole genome, whole exome and targeted sequencing data from patients with chronic lymphocytic leukaemia, on liquid biopsy data from a patient with melanoma and on synthetic data and we found that incorporating information on the timing of tissue collection improves model performance, as long as data of sufficient volume and complexity are available for estimating free model parameters. Thus, our approach is particularly useful when collecting a relatively long sequence of tumour samples is feasible, as in liquid cancers (e.g. leukaemia) and liquid biopsies. The statistical methodology presented in this paper is freely available at github.com/dvav/clonosGP. Supplementary data are available at Bioinformatics online.
- 28 July 2020
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 37 (2) , 147-154
Open AccessA statistical approach for tracking clonal dynamics in cancer using longitudinal next-generation sequencing data
Tumours are composed of distinct cancer cell populations (clones), which continuously adapt to their local micro-environment. Standard methods for clonal deconvolution seek to identify groups of mutations and estimate the prevalence of each group in the tumour, while considering its purity and copy number profile. These methods have been applied on cross-sectional data and on longitudinal data after discarding information on the timing of sample collection. Two key questions are how can we incorporate such information in our analyses and is there any benefit in doing so? We developed a clonal deconvolution method, which incorporates explicitly the temporal spacing of longitudinally sampled tumours. By merging a Dirichlet Process Mixture Model with Gaussian Process priors and using as input a sequence of several sparsely collected samples, our method can reconstruct the temporal profile of the abundance of any mutation cluster supported by the data as a continuous function of time. We benchmarked our method on whole genome, whole exome and targeted sequencing data from patients with chronic lymphocytic leukaemia, on liquid biopsy data from a patient with melanoma and on synthetic data and we found that incorporating information on the timing of tissue collection improves model performance, as long as data of sufficient volume and complexity are available for estimating free model parameters. Thus, our approach is particularly useful when collecting a relatively long sequence of tumour samples is feasible, as in liquid cancers (e.g. leukaemia) and liquid biopsies. The statistical methodology presented in this paper is freely available at github.com/dvav/clonosGP. Supplementary data are available at Bioinformatics online.